

If there was a way to improve the success rate of your phase II and III clinical trials, would you?

My Intelligent Machines delivers a new way to prepare for clinical trials in oncology. We are helping life scientists harness the power of human and artificial intelligence to push the boundaries of drug development.


Reduce costs, time, and failure rates associated with your clinical trials

With MIMs' SaaS product for indication prioritization and biomarker discovery in oncology, you and your team can:

- » Access scientific insights to support strategic decisions on indication prioritization at pre-clinical stage
- » Increase success rate of clinical trials for new targeted and immune therapies
- » Explore new potent combined therapies
- » Accelerate early high-value biomarkers to accelerate companion test development

About our product technology

MIMs' platform integrates our MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, and multi-omic and clinical patient data—and our proprietary GI² algorithm inferring genetic interactions within patient tumors and immune systems. These vivid human cartographies of individual patients deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers.



▶ Patient Classification and Characterization

- Patient clusters
- Molecular and clinical profiles

▶ Target Discovery

- Targets
- Molecular and clinical profiles of good responders

▶ Indication Prioritization for Clinical Trials

- Input: drug target
- Output: % good responders per indication

▶ Biomarker Discovery

- Drug or disease biomarkers - multiomic signatures
- From liquid or solid biopsies

MIMs Platform in Action	Time to results	
	Your life scientist + MIMs platform	Bioinfo outsourcing
Identify genetic interactors of drug target (focus genes)	15 minutes	3 days
Classification of 16,000 patients based on focus genes and patient cluster characterization	16 hours	15 days
Biomarker discovery on a 16,000-patient cohort	2 hours	12 days
Total Time	1 day	30 days
Cost	~\$2.7K	~\$27K

Predict good responders to new therapies with **more than 2X higher performance** than other available methodologies

Generate results at **one tenth of the cost** of consulting services

Complete **a month's work in a single day**

Quantify future trial success to **attract investment**

Move **therapies to the clinic faster**

Key product features and benefits

- » Uses expression data from 16,000 patients across more than 200 cancer types
- » Provides key insights on drug MOAs in individual patient contexts
- » Identifies 30 to 200 genetic interactors of the drug target (focus genes) in minutes
- » Requires the name of the drug target only
- » Outperforms prediction of good responders based on target expression level only
- » Performs equally well for new drug targets and those associated with FDA-approved drugs because MIMs' method is not trained on clinical data
- » Identifies combined therapy opportunities

**Artificial intelligence
in the service of
humans, at bench
and bedside**

About MIMs

MIMs is a software-as-a-service (SaaS) company with an augmented-intelligence platform leveraging systems biology, distributed computing, and machine learning to unleash the power of reverse translational research. Delivering higher performance 30 times faster and at one tenth the cost of other approaches, MIMs is changing the research paradigm for endotype characterization, indications prioritization, and target and biomarker discovery, in oncology, immune-related disorders, infectious diseases, and more.

Schedule a demo to learn more.

info@mims.ai • mims.ai



/ My Intelligent Machines